• 1
    Young JW, Steinman RM. The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation. Stem Cells 1996; 14:37687.
  • 2
    Ilett EJ, Prestwich RJ, Melcher AA. The evolving role of dendritic cells in cancer therapy. Expert Opin Biol Ther 2010; 10:36979.
  • 3
    Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:13847.
  • 4
    Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. Sipuleucel-T. Nat Rev Drug Discov 2010; 9:5134.
  • 5
    Patel PH, Kockler DR. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother 2008; 42:918.
  • 6
    Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2:1096103.
  • 7
    Oyama T, Ran S, Ishida T, Nadaf S, Kerr L, Carbone DP, Gabrilovich DI. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells. J Immunol 1998; 160:122432.
  • 8
    Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34+ cells which suppress immune functions within cancers that secrete granulocyte–macrophage colony-stimulating factor. Clin Cancer Res 1995; 1:95103.
  • 9
    Gandhi R, Anderson DE, Weiner HL. Cutting Edge: immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGF-β-dependent manner. J Immunol 2007; 178:401721.
  • 10
    Serafini P, Meckel K, Kelso M et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203:2691702.
  • 11
    Ozao-Choy J, Ma G, Kao J et al. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009; 69:251422.
  • 12
    Liu WM, Henry JY, Meyer B, Bartlett JB, Dalgleish AG, Galustian C. Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 2009; 101:80312.
  • 13
    Liu WM, Laux H, Henry JY, Bolton TB, Dalgleish AG, Galustian C. A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro. Mol Biol Rep 2010; 37:180114.
  • 14
    Henry JY, Lu L, Adams M, Meyer B, Bartlett B, Dalgleish AG, Galustian C. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate 2012; 72:85667.
  • 15
    Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14:46507.
  • 16
    Galustian C, Meyer B, Labarthe MC et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009; 58:103345.
  • 17
    Haslett PA, Hanekom WA, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003; 187:94655.
  • 18
    Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol Immunother 2004; 53:96377.
  • 19
    Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8+ T cells. J Exp Med 1997; 186:23945.
  • 20
    Jahnisch H, Fussel S, Kiessling A et al. Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol 2010; 2010: 517493.
  • 21
    O'Neill DW. Dendritic cells and T cells in immunotherapy. J Drugs Dermatol 2010; 9:138392.
  • 22
    Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140:3645.
  • 23
    John J, Ismail M, Riley C, Askham J, Morgan R, Melcher A, Pandha H. Differential effects of Paclitaxel on dendritic cell function. BMC Immunol 2010; 11:14.
  • 24
    Amyere M, Mettlen M, Van Der Smissen P, Platek A, Payrastre B, Veithen A, Courtoy PJ. Origin, originality, functions, subversions and molecular signalling of macropinocytosis. Int J Med Microbiol 2002; 291:48794.
  • 25
    Lapalombella R, Andritsos L, Liu Q et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010; 115:261929.
  • 26
    LeBlanc R, Hideshima T, Catley LP et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103:178790.
  • 27
    Chanan-Khan A, Miller KC, Musial L et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24:53439.
  • 28
    Drutman SB, Trombetta ES. Dendritic cells continue to capture and present antigens after maturation in vivo. J Immunol 2010; 185:21406.
  • 29
    Thomas IJ, Petrich de Marquesini LG, Ravanan R et al. CD86 has sustained costimulatory effects on CD8 T cells. J Immunol 2007; 179:593646.
  • 30
    Flesch IE, Stober D, Schirmbeck R, Reimann J. Monocyte inflammatory protein-1α facilitates priming of CD8+ T cell responses to exogenous viral antigen. Int Immunol 2000; 12:136570.